[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"epistaxis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:epistaxis":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,53,75,95,125,148,173],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100643896","phase-1-topical-tor-582-treatment-of-epistaxis-in-hht-100643896",false,"NCT07667413","Topical TOR-582 Treatment of Epistaxis in HHT","A Phase I Trial of TOR-582, a Topical Sirolimus-based Treatment for Epistaxis in Adults With Hereditary Hemorrhagic Telangiectasia","Inclusion Criteria:\n\n1. Age 18 years or older at the time of consent.\n2. Confirmed diagnosis of HHT, defined as meeting at least three of the four Curaçao criteria or preferably by genetic testing.\n3. Moderate nasal epistaxis represented by an Epistaxis Severity Score (ESS) between 3 and 8 at screening, average NOSE-HHT score of 1.01-2, with a self-reported history of at least four spontaneous nosebleeds per week and a cumulative weekly bleeding duration of at least 60 minutes.\n4. Stable nasal hygiene regimen and epistaxis-related medical management for at least 3 months prior to enrollment.\n5. Stable epistaxis pattern for at least 3 months prior to enrollment\n6. Adequate bone marrow function defined as:\n\n   1. Platelet count ≥ 100 × 10⁹\u002FL (≥ 100,000\u002Fmm3)\n   2. WBC count ≥ 2.5 × 10⁹\u002FL at screening (≥ 2,500\u002Fmm3)\n   3. Hgb ≥ 6g\u002FdL with no transfusion in the prior 2 months\n7. INR ≤ 1.4 and activated partial thromboplastin time (aPTT) within institutional normal limits.\n8. Willingness to avoid initiation of other investigational or targeted therapeutic agents for epistaxis (including antiangiogenic or mTOR-modulating therapies) from the time of enrollment through study completion.\n9. Female participants of childbearing potential must have a negative pregnancy test at screening and agree to use effective contraception during the study and for 28 days following the final dose.\n10. Ability to comply with study procedures and follow-up visits, and capacity to provide written informed consent.\n\nExclusion Criteria:\n\n1. Any medical contraindication to systemic sirolimus use.\n2. Prior use of any mTOR inhibitor within the past 3 months.\n3. Endoscopic evaluation of nasal cavity (HES-based)\n\n   1. Site: No numerical site exclusion\n   2. Pattern: AVM-type vascular pattern (HES pattern score = 2).\n   3. Crusting: Moderate to severe nasal crusting (HES crusting score ≥ 2).\n   4. Location: Telangiectasias isolated to the middle or posterior turbinates (HES location score ≥ 2).\n   5. Perforation: Presence of a nasal septal perforation\n4. Surgical cautery or sclerotherapy within the past 3 months prior to enrollment\n5. Vascular embolization of nasal vasculature within the past 3 months prior to enrollment\n6. Clinically significant peripheral vascular disease or circulatory compromise.\n7. Current use of strong CYP3A4 modulators, including inhibitors (e.g., ketoconazole, clarithromycin) or inducers (e.g., rifampin, phenytoin, carbamazepine, St. John's wort).\n8. Use of anti-angiogenic therapies within 30 days prior to screening (e.g., bevacizumab, pazopanib, thalidomide, lenalidomide).\n9. Use of illicit substances within the past 30 days, excluding marijuana.\n10. Use of anticoagulant, antiplatelet, or fibrinolytic medications within the past 30 days, except for low-dose aspirin (81 mg or less).\n11. Use of octreotide or systemic estrogen therapy within the past 30 days.\n12. Clinical laboratory evaluation:\n\n    1. Renal dysfunction, defined as a serum creatinine level greater than 2.0 mg\u002FdL.\n    2. Hepatic impairment, indicated by total bilirubin above 2.0 mg\u002FdL (or above 4.0 mg\u002FdL in patients with a known diagnosis of Gilbert's syndrome) or liver transaminases exceeding three times the upper limit of normal.\n    3. Known SMAD4 mutation with a history of significant gastrointestinal polyposis, unless colonoscopy within the past 18 months demonstrated either no polyps or ≤5 polyps judged to be clinically insignificant by a gastroenterologist.\n13. History of unprovoked venous thromboembolism, confirmed by imaging.\n14. Diagnosis of peripheral neuropathy as confirmed by neurologic evaluation.\n15. Documented hyperproliferative anemia (myelodysplastic syndrome, aplastic anemia, etc.).\n\n    a. Current pregnancy or planned pregnancy within the next 6 months, or active breastfeeding.\n16. Concurrent participation in another interventional research study.\n17. Any condition, circumstance, language, or literacy limitation, that in the judgment of the investigator, would interfere with study participation or completion.","ALL","18 Years",{"count":19,"type":20},27,"ESTIMATED","INTERVENTIONAL",[23],"PHASE1","People with hereditary hemorrhagic telangiectasia (HHT) often experience frequent and severe nosebleeds that can disrupt daily life and lead to anemia, medical procedures, and reduced quality of life. This study is testing a new nasal ointment called TOR-582, which contains sirolimus, to determine whether it can be used safely when applied inside the nose. Adults with HHT and frequent nosebleeds will be invited to participate. Participants will first complete one week of observation without treatment, followed by up to 12 weeks of applying the study ointment inside each nostril twice daily. Different participants will receive different strengths of the ointment so researchers can identify the safest dose. During the study, participants will attend study visits, complete questionnaires about their nosebleeds and quality of life, keep a daily nosebleed diary, undergo nasal examinations, and have blood tests to monitor safety and medication levels. The information gained from this study will help determine whether this topical treatment can be safely studied further and will support the development of a new, less invasive option for managing nosebleeds in people with HHT.",[26,27],"Hereditary Hemorrhagic Telangiectasia (HHT)","Epistaxis",[29,30,27,31,32,33,34,35,36,37,38,39],"Hereditary Hemorrhagic Telangiectasia","HHT","Nosebleeds","Sirolimus","Rapamycin","Topical Sirolimus","Intranasal Therapy","Nasal Telangiectasia","Vascular Malformations","mTOR Inhibitor","Osler-Weber-Rendu Syndrome","RECRUITING","2026-06-18",{"date":43,"type":44},"2026-06-25","ACTUAL",{"date":46,"type":20},"2026-07",{"date":48,"type":20},"2027-05",{"name":50,"class":51},"Columbia University","OTHER",1,{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":57,"acronym":4,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":21,"phases":61,"briefSummary":63,"conditions":64,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":4},"100633806","outcome-of-hyaluronic-acid-gel-versus-petroleum-jelly-in-treatment-of-epistaxis-100633806","NCT07531472","Outcome of Hyaluronic Acid Gel Versus Petroleum Jelly in Treatment of Epistaxis","Inclusion Criteria:\n\n* Patients with anterior localized idiopathic epistaxis\n\nExclusion Criteria:\n\n* Patients wit secondary epistaxis (posttraumatic, postoperative, tumoral).\n* During pregnancy.\n* Patients wit major systemic disease (Blood Disease, Hypertension).",{"count":60,"type":20},50,[62],"NA","The aim of this study is to compare the efficacy of Hyaluronic Acid Gel with Petroleum Jelly in treatment of epistaxis.",[27],"NOT_YET_RECRUITING","2026-04-18",{"date":68,"type":44},"2026-04-22",{"date":70,"type":20},"2026-05-01",{"date":72,"type":20},"2028-06-01",{"name":74,"class":51},"Assiut University",{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":21,"phases":83,"briefSummary":85,"conditions":86,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":4},"100632246","phase-4-the-efficacy-of-local-application-of-b-sitosterol-versus-vasline-in-cases-of-idiopathic-epistaxis-100632246","NCT07511192","The Efficacy of Local Application of B-sitosterol Versus Vasline in Cases of Idiopathic Epistaxis","Inclusion Criteria:\n\n* Patients with recurrent idiopathic anterior epistaxis \\> = 2 episodes in last month\n* No systemic bleeding disorders\n* no nasal trauma or surgery in last months\n\nExclusion Criteria:\n\n* Patients on anticoagulants\n* Systemic disease affecting hemostasis (e.g. liver disease)\n* Known allergy to B-sitosterol or vasline",{"count":82,"type":20},162,[84],"PHASE4","Epistaxis, commonly known as nosebleed, is a frequent otorhinolaryngological complaint, affecting a large proportion of the population. Approximately 60% of individuals experience at least one episode during their lifetime, while around 6% require medical intervention'. The majority of cases are anterior in origin, arising from Kiesselbach's plexus in the anterior nasal septum(2) Idiopathic epistaxis refers to recurrent nasal bleeding without any identifiable local or systemic cause. (3) Factors such as mucosal dryness, minor trauma, inflammation, and environmental conditions can predispose the nasal mucosa to bleeding(4) Maintaining mucosal integrity and hydration is essential in preventing recurrence.\n\nConservative management remains the first-line treatment for anterior epistaxis. Strategies include direct nasal compression, topical vasoconstrictors, nasal packing, and application of moisturizing agents(5) Petroleum jelly (Vaseline) is widely used as a topical agent to maintain hydration, protect the mucosa, and reduce crust formation, thereby minimizing the risk of further bleeding(6) B-sitosterol, a plant-derived phytosterol, has shown anti-inflammatory, immunomodulatory, and tissue-healing properties in several experimental and clinical studies'(7,8) Its anti-inflammatory activity may stabilize the nasal mucosa and enhance repair processes, suggesting a potential therapeutic rol in conditions like idiopathic epistaxis(9) Previous studies hav demonstrated B-sitosterol's efficacy in reducing mucosal inflammation and promoting healing in other mucosal tissues, although its use in ENT applications remains underexplored'(7,8) Considering these properties, B-sitosterol may represent a promising topical alternative to conventional moisturizers such as Vaseline for managing idiopathic epistaxis. This study aims to evaluate and compare the efficacy of local B-sitosterol versus Vaseline in reducing the frequency, duration, and severity of nosebleeds in affected patients.",[27],"2026-04-13",{"date":89,"type":44},"2026-04-15",{"date":91,"type":20},"2026-05",{"date":93,"type":20},"2027-12",{"name":74,"class":51},{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":101,"eligibilityCriteria":102,"healthyVolunteers":103,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":104,"targetDuration":106,"studyType":107,"phases":4,"briefSummary":108,"conditions":109,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":124},"100536012","comprehensive-hht-outcomes-registry-of-the-united-states-chorus-100536012","NCT06259292","Comprehensive HHT Outcomes Registry of the United States (CHORUS)","CHORUS: Comprehensive HHT (Hereditary Hemorrhagic Telangiectasia) Outcomes Registry of the United States","CHORUS","Inclusion Criteria:\n\n* Diagnosed with HHT based on the Curacao diagnostic criteria or genetic testing.\n* Able to provide informed consent or informed consent via a parent or legally authorized representative due to their age or medical condition.\n\nExclusion Criteria:\n\n* Unable to provide informed consent or informed consent via a parent or legally authorized representative.",true,{"count":105,"type":20},10000,"10 Years","OBSERVATIONAL","The Comprehensive HHT Outcomes Registry of the United States (CHORUS) is an observational registry of patients diagnosed with Hereditary Hemorrhagic Telangiectasia (HHT). The purpose of this study is to better understand HHT, the symptoms and complications it causes, and the impact the disease has on people's lives. The investigators will collect long-term information about the participant, allowing us to understand how the disease changes over time, and what factors can influence those changes. Ultimately, this should help improve treatments for the disease.\n\nAnother important goal of the study is to provide a way to contact people to participate in future clinical trials and other research. The registry will be a centralized resource for recruitment for clinical trials. People in the registry will not be obligated to join any of these additional studies, but if interested, can agree to be contacted if they may be eligible for a study.\n\nParticipants will:\n\n* Be asked to provide permission to collect information from their medical records, including things like demographic information, diagnosis information, family history, test results, treatment information, symptoms, complications, lifestyle and other relevant medical information.\n* Be asked study-related questions by phone or at a clinic visit.\n* Be asked study-related questions every year after enrollment for up to 10 years or until the study ends. A member of the study team will communicate with participants by phone or at clinic visits to collect information regarding any changes to their health over the previous year\u002Fs including new test results, treatment information, symptoms, and complications from HHT.",[29,110,111,27,112,113,114],"Arteriovenous Malformations","Telangiectasia","GastroIntestinal Bleeding","Cerebral Arteriovenous Malformations","Vascular Malformation","2025-06-10",{"date":117,"type":44},"2025-06-13",{"date":119,"type":44},"2023-11-13",{"date":121,"type":20},"2033-11",{"name":123,"class":51},"Cure HHT",16,{"id":126,"slug":127,"hasResults":11,"nctId":128,"briefTitle":129,"officialTitle":130,"acronym":4,"eligibilityCriteria":131,"healthyVolunteers":11,"sex":16,"minAge":132,"maxAge":133,"enrollmentInfo":134,"targetDuration":4,"studyType":21,"phases":136,"briefSummary":137,"conditions":138,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":4},"100580346","usage-of-orange-peel-extract-in-management-of-epistaxis-100580346","NCT06836102","Usage of Orange Peel Extract in Management of Epistaxis","The Potential of Nano-based Gel of Orange Peel Extract in Management of Epistaxis : a Randomized Double Blind Clinical Study","Inclusion Criteria:\n\n* children with anterior epistaxis from little's area\n\nExclusion Criteria:\n\n* patient with nasal polyp.\n* patients with hematological abnormalities.\n* patients with general diseases affecting coagulation system.","5 Years","15 Years",{"count":135,"type":20},60,[62],"Efficacy of orange peel extract in treatment of epistaxis in children",[27],"2025-02-15",{"date":141,"type":44},"2025-02-20",{"date":143,"type":20},"2025-02",{"date":145,"type":20},"2025-05",{"name":147,"class":51},"Minia University",{"id":149,"slug":150,"hasResults":11,"nctId":151,"briefTitle":152,"officialTitle":153,"acronym":154,"eligibilityCriteria":155,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":156,"targetDuration":158,"studyType":107,"phases":4,"briefSummary":159,"conditions":160,"keywords":161,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":165,"startDateStruct":167,"completionDateStruct":169,"leadSponsor":171,"locationsCount":52},"100566582","risk-factors-of-epistaxis-recurrence-in-adults-100566582","NCT06657053","Risk Factors of Epistaxis Recurrence in Adults","Facteurs De Risques De Récidive D'épistaxis Chez L'adulte","FREA","Inclusion Criteria:\n\n* Patient who is admitted at the emergency department between 01\u002F2022 and 07\u002F2023 for nose bleeding.\n* Age over 18 yo\n\nExclusion Criteria:\n\n* Opposition to be included\n* Patient who has not his willness to provide opposition to participate.opposition",{"count":157,"type":20},145,"1 Day","We study all patients admitted to the Emergency Department in the Institution between 01\u002F2022 and 07\u002F2023. The information about the recurrence of nose bleeding was searched on their medical file and by calling the patient to confirm ou get the information. Thus, several potentiel risk factors were studied.\n\nThe relation between recurrence and those factors were studied at first individually and then all the significant ones were analyzed with a multivarious statistical test.",[27],[162,163],"Risk Factors","Recurrent Epistaxis","2024-10-22",{"date":166,"type":44},"2024-10-24",{"date":168,"type":20},"2024-11-02",{"date":170,"type":20},"2025-04-01",{"name":172,"class":51},"University Hospital, Grenoble",{"id":174,"slug":175,"hasResults":11,"nctId":176,"briefTitle":177,"officialTitle":177,"acronym":178,"eligibilityCriteria":179,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":180,"targetDuration":4,"studyType":21,"phases":182,"briefSummary":183,"conditions":184,"keywords":185,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":189,"lastUpdatePostDateStruct":190,"startDateStruct":192,"completionDateStruct":194,"leadSponsor":196,"locationsCount":52},"100460924","medico-economic-evaluation-of-management-strategies-for-severe-epistaxis-100460924","NCT05281952","Medico-economic Evaluation of Management Strategies for Severe Epistaxis","EPICOST","Inclusion Criteria:\n\n* Patient with severe epistaxis who failed treatment with double tamponade for more than 48 hours.\n* Patient over 18 years old\n* Affiliated patient or beneficiary of a social security scheme.\n* Patient accepting the principle of randomization\n* Free, informed and written consent, signed by the participant and the investigator (at the latest on the day of inclusion and before any examination required by the research).\n\nExclusion Criteria:\n\n* Patient with epistaxis secondary to facial and\u002For surgical trauma.\n* Patient with epistaxis related to a malignant tumor cause\n* Patient with a history of ligation or embolization\n* Patient under legal protection and\u002For curatorship and\u002For guardianship.\n* Impossibility of giving the person informed information and ensuring the subject's compliance due to impaired physical and\u002For psychological health.\n* Patient participating in another research including an exclusion period still in progress\n* Pregnant or breastfeeding patient\n\nFor non randomized patient\n\n* Patient with a contraindication to general anesthesia: severe and\u002For decompensated cardiac\u002Fhepatic\u002Frenal insufficiency, ASA score 4\n* Severe hemostasis disorders that cannot benefit from correction.\n* History of transient and\u002For definitive stroke of the ischemic type\n* Atheromatous overload",{"count":181,"type":20},180,[62],"Current recommendations consider surgical ligation and supra-selective embolization as equivalent in terms of efficacy and there is no clear consensus to choose between one and the other technique. In the absence of medico-economic studies, these recommendations could not be based on any differences in efficiency between the two techniques. The management of patients with severe non-traumatic epistaxis remains controversial and varies according to the hospital and\u002For university centers. In practice, the use of one or the other technique depends on the habits of each reference center.",[27],[186,187,188],"Severe epistaxis","endoscopic ligation","Supra-selective embolization","2023-08-25",{"date":191,"type":44},"2023-08-29",{"date":193,"type":44},"2023-05-01",{"date":195,"type":20},"2026-12",{"name":197,"class":51},"University Hospital, Toulouse"]